Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
iBio, Inc. completed a disposition involving Otsuka Pharmaceutical Co., Ltd. for $1,000,000 paid at closing (closed 2024-02-25).
- Action
- disposition
- Counterparty
- Otsuka Pharmaceutical Co., Ltd.
- Consideration
- $1,000,000 paid at closing
- Closing
- 2024-02-25
Exact text from the filing
and assumed, all intellectual property rights directly related to the Company’s PD-1 agonist assets (the “PD-1 Assets”) developed or held for development in consideration of $1,000,000 paid at closing (the “Closing Consideration”). The Purchase Agreement also provides for a potential contingent payment of $2,500,000 upon the achievement of specified
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
iBio, Inc. entered into Asset Purchase Agreement with Otsuka Pharmaceutical Co., Ltd. valued at $1,000,000 paid at closing (effective 2024-02-25).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Otsuka Pharmaceutical Co., Ltd.
- Value
- $1,000,000 paid at closing
- Effective
- 2024-02-25
Exact text from the filing
On February 25, 2024, iBio, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”) pursuant to which the Company sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to the Company’s PD-1 agonist assets (the “PD-1 Assets”) developed or held for development in consideration of $1,000,000 paid at closing (the “Closing Consideration”).
View on SEC.gov